+1-888-308-5802     
News Contact Us

Novartis announces Kymriah’s EU approval for blood cancer treatment

Author : Pankaj Singh | Published Date : 2018-08-27 

Novartis International AG has reportedly announced that it has received approval for its cancer therapy called Kymriah, issued by the European Commission. The approved gene-modifying treatment will be used initially to treat young adults up to 25 years of age suffering with B-Cell acute lymphoblastic leukemia and adult patients down with diffuse large B-cell lymphoma.

The one-time therapy that’s said to treat blood cancer by fighting T-cells in the patient’s system, will supposedly modify their bodies to fight off bad cells and then re-infuse new cells. The treatment is also approved in both indications in the United States.

According to sources close to the development, with an investment of $90.39 million Novartis will establish more facilities to continue manufacturing Kymriah. The pharma claimed therapy will cost about $475,000 for patients with acute lymphoblastic leukemia and $373,000 for patients afflicted with diffuse large B-cell lymphoma.

Formerly, Novartis had gained appreciation for its groundbreaking work pertaining to therapy exclusively for dying patients who didn’t respond to other drugs. However, officials were aghast by the prices, which apparently makes Kymriah one of the most expensive treatments.

In the United States, Novartis will only accept charges if patients with lymphoblastic leukemia show signs of recovery by the end of the first month. Meanwhile, discussions in terms of European pricing are still in progress.

In a statement to sources, Novartis revealed that Kymriah’s availability will differ for each country, based on factors like the establishment of licensed facilities for the appropriate indications and completion of a fixed payment agreement.

Post its launch in the United States, the treatment earned $28 million in sales, which is estimated to surpass $1 billion as soon as the demand begins to grow. In the meantime, the pharma firm plans to commence therapies to European patients at least by 2020.

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Facebook admits storing user account passwords in plain text

Published Date: 2019-03-23         Author: Pankaj Singh

The California-based company reaches an estimated 2.7 billion people across the globe with its core social network, messaging applications, and Instagram. Facebook has reportedly admitted that it stored millions of user account passwords in plain text on its internal servers, a faux pas that left... Read More

Cymulate’s BAS platform bags $7.5M in Series A financing round

Published Date: 2019-03-15         Author: Pankaj Singh

The investment will be used to expand Cymulate’s U.S. operations and to enhance its platform’s functionality. Israel-based cybersecurity firm, Cymulate Ltd. has recently raised around $7.5 million in a Series A financing round led by Dell Technologies Capital and Vertex Ventures ... Read More

Rubber processing chemicals industry to exhibit an accelerated growth rate from tire manufacturing applications to 2025, surging automobile production to fuel the industry landscape

Published Date: 2019-02-26         Author: Pankaj Singh

Owing to the ceaseless demand for automobiles over the past three decades, the global rubber processing chemicals industry has witnessed rapid development, specifically from the tire manufacturing segment. A rather fast moving vertical, tire manufacturing involves continuous utilization of chemicals... Read More

© 2019 Fractovia. All Rights Reserved